Prosecution Insights
Last updated: April 19, 2026

Examiner: CHEONG, CHEOM-GIL

Tech Center 1600 • Art Units: 1643 1645 1699

This examiner grants 65% of resolved cases

Performance Statistics

64.7%
Allow Rate
+4.7% vs TC avg
204
Total Applications
+54.9%
Interview Lift
1198
Avg Prosecution Days
Based on 173 resolved cases, 2023–2026

Rejection Statute Breakdown

2.8%
§101 Eligibility
15.4%
§102 Novelty
24.4%
§103 Obviousness
36.4%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
18183042 ENGINEERED ANTIBODIES AND USES THEREOF Non-Final OA The Regents of the University of California
18150466 ALTERNATIVE SURFACTANTS AS STABILIZERS FOR THERAPEUTIC PROTEIN FORMULATIONS Final Rejection Hoffmann-La Roche Inc.
16979209 COMPOSITIONS AND METHODS FOR DETECTING MYCOBACTERIUM TUBERCULOSIS Final Rejection THE JOHNS HOPKINS UNIVERSITY
17769113 CHAGAS DISEASE VACCINE ANTIGENS WITH IMPROVED STABILITY AND DECREASED AGGREGATION Non-Final OA Baylor College of Medicine
18292771 COMPOSITION COMPRISING A PARTICULAR ANTIOXIDANT, A SPECIFIC FATTY ACID ESTER, A BIFIDOBACTERIUM SPECIES LYSATE AND A YEAST EXTRACT Non-Final OA L'Oreal
18033813 PROTEINS FOR THE DETECTION OF SCHISTOSOMA INFECTION Non-Final OA MERCK PATENT GMBH
18258550 IMPLANTABLE CONSTRUCTS FOR MODULATING AN IMMUNE RESPONSE Non-Final OA William Marsh Rice University
18002245 METHOD FOR OBTAINING A COMPOSITION COMPRISING HUMAN PLASMA-DERIVED IMMUNOGLOBULIN M Non-Final OA GRIFOLS WORLDWIDE OPERATIONS LIMITED
17680155 LIQUID PHARMACEUTICAL COMPOSITION Non-Final OA FRESENIUS KABI DEUTSCHLAND GMBH
18357065 COMPOSITIONS AND METHODS FOR DETECTING TRYPANOSOMA CRUZI INFECTION Non-Final OA University of Georgia Research Foundation, Inc.
18599008 BIOMARKERS FOR EARLY DIAGNOSIS AND DIFFERENTIATION OF MYCOBACTERIAL INFECTION Non-Final OA WISCONSIN ALUMNI RESEARCH FOUNDATION
16771510 Inducible Cell Receptors for Cell-Based Therapeutics Non-Final OA Trustees of Boston University
18427000 MANUFACTURING METHODS FOR PRODUCING ANTI-IL12/IL23 ANTIBODY COMPOSITIONS Final Rejection Janssen Biotech, Inc.
17771420 THERANOSTICS FOR HYPERTENSION INDUCED MYOCARDIAL MICROBLEEDS Non-Final OA BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE
18625004 ANTIBODIES AGAINST CLAUDIN 18.2 USEFUL IN CANCER DIAGNOSIS Non-Final OA TRON-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz
17632270 PROCESS FOR PREPARING A COMPOSITION COMPRISING A PROTEIN D POLYPEPTIDE Final Rejection GLAXOSMITHKLINE BIOLOGICALS SA
18564618 INDICATOR MOLECULE FOR TOXIGENICITY OF AFLATOXIGENIC FUNGI AND USE THEREOF Non-Final OA OIL CROPS RESEARCH INSTITUTE, CHINESE ACADEMY OF AGRICULTURAL SCIENCES
17675775 VARIANT FC DOMAINS AND USES THEREOF Non-Final OA Cidara Therapeutics, Inc.
17915661 COMPOSITION FOR IMPROVING SKIN WRINKLE, MOISTURIZING, STRENGTHENING SKIN BARRIER, AND PROMOTING SKIN REGENERATION, COMPRISING MIXED LACTIC ACID BACTERIA AS ACTIVE INGREDIENT Non-Final OA PFNATURE CO., LTD.
16428856 ANTI-PVRIG/ANTI-TIGIT BISPECIFIC ANTIBODIES AND METHODS OF USE Non-Final OA Compugen Ltd.
18187377 THERAPEUTIC MOLECULES Final Rejection PetMedix Ltd
18023492 ANTITUMOR BACTERIAL STRAIN, AND COMPOSITION AND METHOD USING SAME Non-Final OA LIVEOME INC.
17758399 PROGRAMMED CELL DEATH RECEPTOR 1 ANTIBODY FORMULATION AND USE THEREOF Final Rejection SHANGHAI HENLIUS BIOTECH, INC.
17255570 METHODS OF TREATING OR PREVENTING MUCORMYCOSIS Non-Final OA Los Angeles Biomedical Research Institute at Harbor at UCLA Medical Center
16823313 INSECT PRODUCTION SYSTEMS AND METHODS Non-Final OA INSECTERGY US LLC

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month